Work

Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study

Year: 2022

Type: erratum

Source: Nature Metabolism

DOI: 10.1038/s42255-022-00635-4

Authors: Marja K. Puurunen, Jerry Vockley, Shawn L. Searle, Stephanie J. Sacharow, John A. Phillips, William S. Denney, Benjamin D. Goodlett, David A. Wagner, Larry Blankstein, Mary J. Castillo, Mark R. Charbonneau, Vincent M. Isabella, Vasu V. Sethuraman, Richard J. Riese, Caroline B. Kurtz, Aoife M. Brennan

Institutions: Synlogic (United States), University of Pittsburgh, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, PRA Health Sciences, Boston Children's Hospital, Harvard University, Vanderbilt University Medical Center, Metabolic Solutions

Language: English

Topic: Metabolism and Genetic Disorders

Subfield: Clinical Biochemistry

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4291972500

Cites:

Cited by: 4

Related to: 10